← Back to all signals
RESEARCH PAPER ANALYSIS

The formaldehyde dispute - Part B: scientific critique of EPA's formaldehyde occupational exposure values (OEVs) and proposed alternative occupational exposure limits (OELs).

AI interpretation is pending for this paper.

Open original publication →
PMID42101930
JournalCritical reviews in toxicology
Publication Date2026-05-08
Ingested2026-08-02 12:06 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

In 2024, the U.S. Environmental Protection Agency (EPA) finalized its Integrated Risk Information System (IRIS) Toxicological Review and Toxic Substances Control Act (TSCA) Risk Evaluation for formaldehyde. After analyzing all the data that they deemed relevant, TSCA relied on IRIS's proposed inhalation reference values to establish an 8-hour occupational exposure value (OEV) of 0.11 ppm derived from epidemiological evidence of nasopharyngeal cancer. They also developed a 15-minute OEV of 0.17 ppm based on the goal of preventing sensory irritation. In an earlier draft of EPA's TSCA Risk Evaluation, they initially proposed an 8-hour OEV of 0.011 ppm derived from residential exposure studies of children, but this was withdrawn. This review examined EPA's methodology, the nearly 40 years of scientific literature underlying the EPA's conclusions, and the more than 300 public comments, which were submitted to the draft IRIS Toxicological Review (Docket ID: [EPA-HQ-ORD-2010-0396]) and draft TSCA Risk Evaluation (Docket ID: [EPA-HQ-OPPT-2023-0613]). A minimum of five significant flaws were identified and discussed: (1) heavy reliance on epidemiological studies which had serious confounding factors and design limitations; (2) application of default uncertainty factors which were too high given the robust human data; (3) use of exclusion criteria which dismissed high-quality studies from being considered; (4) the use of a linear no-threshold (LNT) model despite decades of substantial evidence for a threshold-driven mode of action (MOA); and (5) neglect for a validated biologically based dose-response (BBDR) model which may have been the most robust ever developed. Based on our weight-of-evidence evaluation of toxicological, mechanistic, and epidemiological data, we propose occupational exposure limits (OELs) of 0.3 ppm (8-hour TWA) and 1 ppm (15-min STEL). These values are grounded in controlled human exposure studies of asthmatics and non-asthmatics and supported by an internationally accepted BBDR model estimating an approximately 1 in 940,000 increased cancer risk for workers. As such, these OELs protect against sensory irritation, asthma, and other adverse effects, as well as carcinogenicity. They are also aligned with limits adopted by other domestic and international regulatory bodies. Immediately before this paper was accepted, EPA released their Updated Draft Risk Calculation Memorandum: Formaldehyde for public comment, which proposed to drop their promulgated OEVs (0.11 ppm and 0.17 ppm) and adopt an 8-hour OEV of 0.3 ppm to protect against sensory irritation and cancer, similarly to what was recommended in this paper.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Late cardiopulmonary morbidity in patients with Hodgkin lymphoma: a retrospective nationwide registry study. Annals of hematology 66.6 2 Endoscopic techniques for removal of intraorbital foreign bodies - a clinical series. Acta neurochirurgica 60.9 3 Existing 'In-Between': A Qualitative Exploration of Individual, Interpersonal and Structural Influences on Empowerment Among Young Adults With Chronic Health Conditions. Health expectations : an international journal of public participation in health care and health policy 57.5 4 Transcriptome Analysis Identifies a Myeloid-Like Signature in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy. Cancer medicine 83.78 5 Combined ATR and mitotic inhibition is effective against MYCN-amplified neuroblastoma. Molecular cancer therapeutics 59.9 6 Computational identification of phytochemical NMDAR pore-targeting candidates for radiation-induced cognitive decline. In silico pharmacology 63.2 7 Examining the roles of socioeconomic status and relevant health correlates (body mass index, diet quality, and inflammation) for neuropsychological function in young adults. Acta neuropsychiatrica 65.0 8 Unexpected Adverse Events During Anti-GD2 Immunotherapy Following T- and B-Cell Depleted Haploidentical Transplantation in High-Risk Neuroblastoma: A Pediatric Case Report. Pediatric blood & cancer 47.64 9 Feeding, Fear, and Acceptance: Caregivers' Experiences of Nutritional Support During Childhood Cancer Treatment. Pediatric blood & cancer 59.24 10 Cardio-protection and monitoring for early phase clinical trials: Recommendations from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Journal of the National Cancer Institute 82.34 11 Beyond Molecular Diagnosis: Integrating Therapeutic Drug Monitoring and Pharmacogenetics for Precision Use of Tyrosine Kinase Inhibitors in Pediatric Hematological Malignancies. Therapeutic drug monitoring 55.06 12 Re: Erbas IM: Reconsidering the Interpretation of Thyroid Cancer Risk in Pediatric Hashimoto Thyroiditis. Hormone research in paediatrics 47.5 13 Hepatocellular carcinoma screening in a tertiary hospital. What are we missing? Oncology 68.2 14 Infection in Pediatric Auditory Brainstem Implant: A Case Study and Scoping Review. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 51.9 15 Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer cell 48.85 16 Why Complete Pediatric Cancer Registration in Germany Requires Cross-Sector Reporting Obligations: A Registry Comparison Study. Klinische Padiatrie 57.5 17 Nail disorders in pediatric patients: Part 2. Clinical overview, diagnosis and management of inflammatory, pigmentary, and neoplastic etiologies. Journal of the American Academy of Dermatology 54.0 18 The Maternal-Placental-Fetal Liver Axis: A Mechanistic Framework for Understanding Benzene Developmental Hematotoxicity. Reproductive toxicology (Elmsford, N.Y.) 39.62 19 A Pediatric Case of Malignant Melanoma Successfully Treated With Adjuvant Nivolumab. The Journal of dermatology 47.5 20 Management of seizures in patients with brain tumors. Current opinion in neurology 76.7 21 Paraneoplastic Autoimmune Multiorgan Syndrome: Diagnostic Lessons for Pediatricians. Pediatrics 62.0 22 Intraparotid lipoma in a 15-year-old girl: MRI-based diagnosis of a rare parotid lesion. Radiology case reports 56.0 23 Pathways from chronic stress to cognitive decline: A multi-cohort mediation analysis of inflammation and immune-related gene expression. Brain, behavior, & immunity - health 49.1 24 High-Resolution Ultrasound in the Evaluation of Median and Superficial Radial Nerve Involvement in Neurofibromatosis Type 1. Ultrasound quarterly 54.0 25 Pacak-Zhuang syndrome with EPAS1 p.Pro531Leu somatic variant: one case report and literature review. Hematology (Amsterdam, Netherlands) 50.9 26 Beyond the Bones: Primary Prostatic Synovial Sarcoma in a Young Adult. Cureus 65.2 27 Multiple Extensive Odontogenic Keratocysts in a Child With Gorlin-Goltz Syndrome: A Case Report. Cureus 51.4 28 Behavior Change Interventions to Promote Healthy Lifestyles Among Adolescent and Young Adult Childhood Cancer Survivors: A Scoping Review. Cancer reports (Hoboken, N.J.) 61.2 29 [Survey on serum tetanus antibody levels in children with hematological malignancies post-chemotherapy in Zhejiang Province from 2022 to 2023]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 72.6 30 Utility of thyroid nodule to thyroid lobe volume ratio to measure fine needle aspiration cytologic malignancy risk of thyroid nodules in the pediatric population. International journal of pediatric otorhinolaryngology 68.5 31 Implementation of a universal psychosocial screening program across the pediatric cancer treatment trajectory: a standard of care. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 62.74 32 Conjunctival involvement with corneal extension in pediatric mycosis fungoides. Surgical and immunomodulatory management. Archivos de la Sociedad Espanola de Oftalmologia 60.0
PATIENT-FRIENDLY SUMMARY

The formaldehyde dispute - Part B: scientific critique of EPA's formaldehyde occupational exposure values (OEVs) and proposed alternative occupational exposure limits (OELs).

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic